Of note, at the time of discontinuation due to disease progression, males exhibited significantly higher levels of CRP compared to females, suggesting a possible significant sex-related predictive impact on survival outcomes in lung cancer patients treated with ICIs. This evidence concerns the gene CRP and lung carcinoma.